Defence Therapeutics’ AccuTOX Enhances Cancer Treatment
Company Announcements

Defence Therapeutics’ AccuTOX Enhances Cancer Treatment

Defence Therapeutics (TSE:DTC) has released an update.

Defence Therapeutics Inc. has announced that its AccuTOX® technology not only kills tumors but also boosts the immune system, significantly enhancing the effectiveness of Immune Checkpoint Inhibitors (ICI) in treating solid tumors. AccuTOX® achieves this by converting ‘cold’ tumors, which typically resist ICI treatment, into ‘hot’ tumors that are more vulnerable to immune attack. The company has observed a tenfold increase in treatment efficacy in preclinical studies and sees AccuTOX® as a potential game-changer for increasing the patient population eligible for ICI treatment.

For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskDefence Therapeutics Enhances Leadership for Growth
TipRanks Canadian Auto-Generated NewsdeskDefence Therapeutics Innovates in Diabetes and Obesity Treatment
TipRanks Canadian Auto-Generated NewsdeskDefence Therapeutics Innovates in Cancer Radiotherapy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App